Allogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies Post author:andrewkaretas Post published:February 12, 2025 Post category:CD19/Scientific Publications Continue ReadingAllogeneic Chimeric Antigen Receptor T‑Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B‑Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies
Supplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies Post author:andrewkaretas Post published:February 12, 2025 Post category:CD19/Scientific Publications Continue ReadingSupplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies
March 5, 2025 11:50 AM EST : TD Cowen 45th Annual Health Care Conference Post author:andrewkaretas Post published:February 11, 2025 Post category:Events Continue ReadingMarch 5, 2025 11:50 AM EST : TD Cowen 45th Annual Health Care Conference
February 12, 2025 3:20 PM EST : Oppenheimer 35th Annual Healthcare Life Sciences Conference Post author:andrewkaretas Post published:February 11, 2025 Post category:Events Continue ReadingFebruary 12, 2025 3:20 PM EST : Oppenheimer 35th Annual Healthcare Life Sciences Conference
January 15, 2025 6:00 PM EST : 43rd Annual J.P. Morgan Healthcare Conference Post author:andrewkaretas Post published:January 13, 2025 Post category:Events Continue ReadingJanuary 15, 2025 6:00 PM EST : 43rd Annual J.P. Morgan Healthcare Conference
Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy Post author:andrewkaretas Post published:December 9, 2024 Post category:CD19/Scientific Publications Continue ReadingAlpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cema‑Cel) in Patients With Large B‑Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy
December 2, 2024 11:00 AM EST : The Citizens JMP Hematology and Oncology Summit Post author:andrewkaretas Post published:November 27, 2024 Post category:Events Continue ReadingDecember 2, 2024 11:00 AM EST : The Citizens JMP Hematology and Oncology Summit
December 3, 2024 8:00 AM EST : Piper Sandler 36th Annual Healthcare Conference Post author:andrewkaretas Post published:November 27, 2024 Post category:Events Continue ReadingDecember 3, 2024 8:00 AM EST : Piper Sandler 36th Annual Healthcare Conference
November 20, 2024 6:30 AM EST : Jefferies London Healthcare Conference Post author:andrewkaretas Post published:November 20, 2024 Post category:Events Continue ReadingNovember 20, 2024 6:30 AM EST : Jefferies London Healthcare Conference
November 18, 2024 8:35 AM EST : Stifel 2024 Healthcare Conference Post author:andrewkaretas Post published:November 18, 2024 Post category:Events Continue ReadingNovember 18, 2024 8:35 AM EST : Stifel 2024 Healthcare Conference
